This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MN-305

MediciNova, Inc.

Drug Names(s): Ozemozotan, MKC-242

Description: MN-305 is a highly-selective full agonist at the serotonin 5-HT1A receptor.

Deal Structure: MediciNova and Mitsubishi Tanabe
MediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries. The data acquired from Mitsubishi includes extensive preclinical and clinical safety results, including that from full carcinogenicity testing in rodents.

In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.

As of May 2014, Mitsubishi Tanabe's pipeline indicates that the licensing agreement involving MKC-242 has been terminated. We assume this refers to the agreement between MediciNova and Mitsubishi Tanabe.

Partners: Mitsubishi Tanabe Pharma Corporation


MN-305 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug